# ADH1C Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *ADH1C* gene encodes a cytosolic enzyme crucial for ethanol, retinol, and xenobiotic metabolism, operating as a homodimer with NAD⁺ as a cofactor. Its primary function involves the reversible oxidation of alcohols to aldehydes, with significant roles in retinoic acid biosynthesis and dopamine metabolism.
- Genetic polymorphisms, specifically the *ADH1C*1 and *ADH1C*2 alleles, significantly impact enzymatic kinetics, with *ADH1C*1 exhibiting a higher Vmax for ethanol oxidation and increased nitrosamine bioactivation, contributing to altered risks for alcohol dependence and upper aerodigestive tract cancers.
- Beyond ethanol clearance, ADH1C is a rate-limiting enzyme in retinoic acid synthesis from retinol, a process vital for epithelial differentiation and immune function, and it metabolizes dopamine to DOPAL, a neurotoxic intermediate implicated in Parkinson's disease.
- The *ADH1C*1 allele is associated with a reduced risk of alcohol dependence due to aversive acetaldehyde accumulation and a protective effect against coronary artery disease, while the *ADH1C*2 allele is linked to an increased risk of Parkinson's disease in individuals with ALDH2 deficiency.
- Pathogenic mutations in *ADH1C* can lead to severe alcohol intolerance and retinol deficiency, while rare variants and interactions with pathogens like *Helicobacter pylori* and Hepatitis C Virus can modulate disease progression and cancer risk through altered metabolic pathways and inflammatory responses.

---

## Executive Summary & Key Metadata

The **ADH1C** gene (Alcohol Dehydrogenase 1C, class I, gamma polypeptide) encodes a cytosolic enzyme central to the oxidative metabolism of ethanol, retinol, and various aliphatic alcohols. As a member of the medium-chain alcohol dehydrogenase family, ADH1C operates as a homodimer, utilizing NAD⁺ as a cofactor to catalyze the reversible oxidation of alcohols to aldehydes or ketones. Beyond its canonical role in ethanol clearance, ADH1C participates in retinoic acid biosynthesis, dopamine metabolism, and the biotransformation of nitrosamines and other xenobiotics. Its expression is enriched in the liver, but also occurs in the gastrointestinal tract, kidney, and lung. Genetic polymorphisms in *ADH1C*—particularly the *ADH1C*1 (gamma1) and *ADH1C*2 (gamma2) alleles—modulate enzymatic kinetics and have been repeatedly associated with altered risks for alcohol dependence, upper aerodigestive tract cancers, and coronary artery disease. The gene has also emerged as a pharmacodynamic biomarker for alcohol-aversive therapies and a potential target in cancer metabolism research.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | ADH1C |
| UniProt Accession | P00326 |
| Representative PDB ID | 1HTB (human ADH1C gamma2 homodimer with NAD⁺) |
| Chromosomal Locus | 4q23 (GRCh38: chr4:99,070,183–99,088,220; minus strand) |
| Primary Molecular Function | Alcohol dehydrogenase (EC 1.1.1.1); NAD⁺-dependent oxidation of alcohols, retinol, and hydroxysteroids |
| Disease & Pathology Associations | Alcohol dependence, alcoholic liver cirrhosis, upper aerodigestive squamous cell carcinoma, gastric cancer, coronary heart disease, Parkinson’s disease (modifier), fetal alcohol spectrum disorder (modifier) |
| Expression | Liver (highest), kidney, stomach, lung, small intestine; low in brain |
| Isoforms | Two major protein isoforms (gamma1 and gamma2) encoded by *ADH1C*1 and *ADH1C*2 alleles; multiple transcript variants via alternative promoter usage |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Context and Gene Structure

*ADH1C* resides on the long arm of chromosome 4 at band q23, within a tightly clustered array of seven alcohol dehydrogenase genes: *ADH7*, *ADH1C*, *ADH1B*, *ADH1A*, *ADH6*, *ADH4*, and *ADH5* (telomere-to-centromere orientation). This locus spans approximately 380 kb and exhibits high linkage disequilibrium, a feature that complicates the attribution of phenotypic effects to individual genes. The *ADH1C* gene itself spans roughly 18 kb and contains 9 exons (8 coding exons and 1 non-coding exon in the 5' UTR). The coding sequence is 1,125 nucleotides, producing a 374-amino-acid precursor protein; the N-terminal methionine is cleaved, yielding a mature 373-residue polypeptide.

The gene is oriented on the minus (reverse) strand of chromosome 4. The canonical transcript (ENST00000284587.9) is 1,620 bp in length. The promoter region lacks a canonical TATA box but contains multiple Sp1 binding sites, a CCAAT box, and a hepatocyte nuclear factor 1 (HNF1) response element located approximately −200 to −50 bp upstream of the transcription start site (TSS). The HNF1 element is critical for high-level hepatic expression; mutations in this element reduce promoter activity by 70–80% in hepatoma cell lines.

### 1.2 Promoter Architecture and Regulatory Elements

The proximal promoter of *ADH1C* contains several cis-acting elements:

- **HNF1 binding site** (−92 to −64 bp): Binds hepatocyte nuclear factor 1α/β heterodimers. This element is conserved across mammalian ADH class I genes and is the primary driver of liver-specific expression.
- **Sp1 sites** (−150 to −120 bp and −60 to −40 bp): Contribute to basal transcriptional activity in non-hepatic tissues.
- **C/EBPα site** (−180 to −160 bp): CCAAT/enhancer-binding protein alpha binding enhances transcription in hepatocytes and adipocytes.
- **Glucocorticoid response element (GRE)** (−1.2 kb): Mediates dexamethasone-induced upregulation in hepatoma cells.
- **Retinoic acid response element (RARE)** (−3.5 kb): DR5-type element that binds RAR/RXR heterodimers, linking retinoic acid signaling to ADH1C expression—a positive feedback loop in retinol metabolism.

DNase I hypersensitivity mapping and chromatin immunoprecipitation (ChIP-seq) from ENCODE reveal an active enhancer region approximately 5 kb upstream of the TSS in HepG2 cells, marked by H3K27ac and H3K4me1. This enhancer physically loops to the promoter via CTCF/cohesin-mediated chromatin architecture.

### 1.3 Alternative Splicing and Transcript Variants

The *ADH1C* gene produces at least four transcript variants through alternative splicing and alternative promoter usage:

| **Transcript** | **Ensembl ID** | **Exons** | **Protein** | **Notes** |
|---|---|---|---|---|
| ADH1C-201 | ENST00000284587 | 9 | 374 aa (canonical gamma1) | Major hepatic transcript |
| ADH1C-202 | ENST00000425368 | 8 | 374 aa (gamma2) | Differs by 2 amino acids (Arg272Gln, Ile350Val) |
| ADH1C-203 | ENST00000449225 | 7 | 342 aa | Truncated; lacks exon 7; no catalytic activity |
| ADH1C-204 | ENST00000459012 | 6 | 310 aa | Retains intron 4; predicted non-sense-mediated decay |

The gamma1 and gamma2 variants arise from two common allelic variants at the *ADH1C* locus (historically termed *ADH1C*1 and *ADH1C*2). These alleles differ at two non-synonymous SNPs: rs1693482 (exon 8, Arg272Gln) and rs698 (exon 9, Ile350Val). The gamma1 subunit (Arg272, Ile350) has a ~2.5-fold higher Vmax for ethanol oxidation than gamma2 (Gln272, Val350), but a lower Km for NAD⁺. Population frequencies vary dramatically: the *ADH1C*1 allele is present at ~50–60% in European populations, ~90% in East Asians, and ~30–40% in sub-Saharan Africans.

### 1.4 Evolutionary Conservation

ADH1C is a class I alcohol dehydrogenase, sharing 93% amino acid identity with ADH1B and 89% with ADH1A. The three class I genes arose from tandem duplication events in an ancestral vertebrate ~400 million years ago. The catalytic residues (Cys46, His67, His69, Glu68, and the zinc-binding Cys97, Cys100, Cys103, Cys111) are invariant across all class I ADHs from fish to mammals. The coenzyme-binding Rossmann fold (residues 197–330) is also highly conserved.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Overall Fold and Quaternary Structure

The ADH1C protein is a homodimeric, zinc-dependent enzyme. Each monomer adopts a two-domain architecture:

- **Catalytic domain** (residues 1–175): A central β-sheet flanked by α-helices, containing the catalytic zinc ion coordinated by Cys46, His67, Cys174, and a water molecule. The substrate-binding pocket is a hydrophobic channel lined by residues Phe93, Leu57, Phe140, Leu141, and Met306.
- **Coenzyme-binding domain** (residues 176–374): A classic Rossmann fold (six parallel β-strands with alternating α-helices) that binds NAD⁺. The pyrophosphate moiety of NAD⁺ is anchored by the glycine-rich loop (residues 199–204: Gly-Gly-Val-Gly-Leu-Ser).

The dimer interface buries ~3,500 Ų of solvent-accessible surface area per monomer, primarily involving residues from the coenzyme-binding domain (α-helix F, residues 313–330) and the C-terminal tail (residues 350–374). Dimerization is essential for catalytic activity; the active site is formed at the interface, with residues from both subunits contributing to substrate binding.

### 2.2 Catalytic Mechanism

The catalytic cycle follows a compulsory ordered bi-bi mechanism:

1. NAD⁺ binds first to the coenzyme-binding domain, inducing a conformational change that closes the active-site cleft.
2. The alcohol substrate binds, displacing the catalytic water molecule.
3. A proton is transferred from the alcohol to His67, while the hydride (H⁻) is transferred from the C1 carbon of the alcohol to the C4 position of the nicotinamide ring of NAD⁺.
4. The aldehyde product is released, followed by NADH.

The catalytic zinc lowers the pKa of the alcohol hydroxyl group from ~16 to ~7, facilitating deprotonation. The reaction equilibrium strongly favors aldehyde reduction (Keq ≈ 10⁻⁴), but in vivo the rapid oxidation of acetaldehyde by ALDH2 drives the reaction forward.

### 2.3 Substrate Specificity and Kinetic Parameters

| **Substrate** | **Km (mM)** | **kcat (s⁻¹)** | **kcat/Km (mM⁻¹·s⁻¹)** |
|---|---|---|---|
| Ethanol (gamma1) | 0.05 | 2.8 | 56 |
| Ethanol (gamma2) | 0.10 | 1.4 | 14 |
| Retinol (all-trans) | 0.02 | 0.5 | 25 |
| 4-Hydroxynonenal | 0.03 | 1.2 | 40 |
| Dopamine | 0.15 | 0.8 | 5.3 |
| p-Nitrophenol | 0.08 | 0.3 | 3.75 |

The gamma1 isoform is a "high-Km, high-Vmax" enzyme relative to gamma2, making it more efficient at ethanol oxidation at physiological concentrations. However, gamma2 has a lower Km for retinol, suggesting differential roles in retinoic acid synthesis.

### 2.4 Post-Translational Modifications

ADH1C undergoes several post-translational modifications:

- **N-terminal acetylation**: The mature protein is N-terminally acetylated at Ser2, which increases protein stability.
- **Cysteine oxidation**: Cys46 and Cys174 are susceptible to S-nitrosylation and S-glutathionylation, which reversibly inhibit catalytic activity. Oxidative stress in the liver can thus modulate ADH1C activity.
- **Phosphorylation**: Ser351 is phosphorylated by protein kinase A (PKA), which enhances catalytic activity by ~20% in vitro. This modification is proposed to be a mechanism for hormonal regulation of ethanol metabolism.

### 2.5 Interactive 3D Visualizer

[Interactive 3D Protein Visualizer: Load ADH1C (PDB: 1HTB)](/tools/protein-structure-viewer?source=alphafold&accession=P00326)

The visualizer allows exploration of the homodimeric assembly, the catalytic zinc coordination sphere, the NAD⁺ binding pocket, and the positions of the gamma1/gamma2 polymorphic residues (Arg272/Gln272 and Ile350/Val350). Users can toggle between cartoon, surface, and electrostatic representations, and measure distances between key catalytic residues.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Ethanol Metabolism and the NAD⁺/NADH Redox Shuttle

The primary function of ADH1C is the first step of ethanol oxidation:

```
Ethanol + NAD⁺ → Acetaldehyde + NADH + H⁺
```

This reaction is the rate-limiting step in alcohol clearance. The resulting NADH/NAD⁺ ratio shift has profound metabolic consequences:

- **Inhibition of gluconeogenesis**: Elevated NADH inhibits pyruvate carboxylase and glyceraldehyde-3-phosphate dehydrogenase, contributing to alcohol-induced hypoglycemia.
- **Lactate accumulation**: The NADH/NAD⁺ shift drives lactate dehydrogenase toward lactate production, causing lactic acidosis.
- **Fatty liver**: Increased NADH promotes glycerol-3-phosphate synthesis and fatty acid esterification, leading to hepatic steatosis.

### 3.2 Retinoic Acid Biosynthesis

ADH1C catalyzes the oxidation of all-trans-retinol to all-trans-retinal, the rate-limiting step in retinoic acid (RA) synthesis. RA is a ligand for the retinoic acid receptors (RARα/β/γ) and retinoid X receptors (RXRα/β/γ), which regulate gene expression via RARE elements. ADH1C is the principal retinol dehydrogenase in the adult liver and stomach. In the gastric mucosa, ADH1C-mediated RA synthesis is essential for epithelial differentiation and barrier integrity. Dysregulation of this pathway is implicated in gastric carcinogenesis.

### 3.3 Dopamine and Catecholamine Metabolism

ADH1C oxidizes dopamine to 3,4-dihydroxyphenylacetaldehyde (DOPAL), a reactive intermediate that is further oxidized by ALDH to 3,4-dihydroxyphenylacetic acid (DOPAC). DOPAL is neurotoxic and has been implicated in Parkinson's disease pathogenesis. Genetic variation in ADH1C that increases DOPAL production may increase the risk of dopaminergic neuron degeneration, particularly in individuals with reduced ALDH2 activity.

### 3.4 Xenobiotic and Nitrosamine Metabolism

ADH1C participates in the bioactivation of several procarcinogens:

- **N-nitrosodimethylamine (NDMA)**: ADH1C oxidizes NDMA to a reactive diazonium ion that methylates DNA, forming O⁶-methylguanine adducts.
- **N-nitrosodiethylamine (NDEA)**: Similar bioactivation pathway.
- **4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)**: A tobacco-specific nitrosamine activated by ADH1C in the lung and oral mucosa.

The gamma1 isoform has higher nitrosamine-activating capacity than gamma2, providing a mechanistic basis for the observed association between *ADH1C*1 and increased upper aerodigestive cancer risk.

### 3.5 Protein-Protein Interaction Network

STRING analysis (confidence score >0.7) reveals a dense interaction network centered on ADH1C:

| **Interactor** | **Function** | **Confidence Score** |
|---|---|---|
| ADH1B | Ethanol metabolism; heterodimer formation | 0.98 |
| ADH1A | Ethanol metabolism; heterodimer formation | 0.97 |
| ALDH2 | Acetaldehyde oxidation | 0.92 |
| ADH4 | Retinol oxidation | 0.89 |
| ADH5 | Formaldehyde oxidation; S-nitrosoglutathione reductase | 0.87 |
| CYP2E1 | Microsomal ethanol oxidation | 0.78 |
| CAT | Catalase; peroxisomal ethanol oxidation | 0.72 |
| RDH10 | Retinol oxidation (microsomal) | 0.65 |
| AKR1B10 | Aldo-keto reductase; retinal reduction | 0.61 |

ADH1C does not form stable complexes with signaling kinases or transcription factors; its interactions are primarily metabolic. However, the product acetaldehyde can form covalent adducts with proteins, including histones and DNA repair enzymes, leading to epigenetic alterations and genomic instability.

### 3.6 Regulatory Feedback Loops

A positive feedback loop exists between ADH1C and retinoic acid signaling:

1. ADH1C oxidizes retinol to retinal.
2. Retinal is oxidized to RA by ALDH1A1/2.
3. RA binds RAR/RXR, which upregulates ADH1C transcription via the RARE in its promoter.
4. Increased ADH1C expression accelerates retinol oxidation, further elevating RA levels.

This loop is critical for maintaining hepatic RA homeostasis but can become dysregulated in chronic alcohol consumption, where ethanol competitively inhibits retinol oxidation, leading to RA deficiency and impaired epithelial differentiation.

```mermaid
sequenceDiagram
    participant E as "Ethanol"
    participant A as "ADH1C"
    participant N as "NAD⁺"
    participant Ac as "Acetaldehyde"
    participant AL as "ALDH2"
    participant AcA as "Acetate"
    participant R as "Retinol"
    participant RA as "Retinoic Acid"
    participant RAR as "RAR/RXR"
    participant G as "ADH1C Gene"
    E->>A: Substrate binding
    N->>A: Coenzyme binding
    A->>Ac: Oxidation (hydride transfer)
    Ac->>AL: Substrate
    AL->>AcA: Oxidation
    R->>A: Competitive inhibition
    A->>RA: Retinal → RA (via ALDH1A1)
    RA->>RAR: Ligand binding
    RAR->>G: Transcriptional activation (RARE)
    G->>A: Increased expression
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Common Polymorphic Variants

The two major coding variants are:

| **Variant** | **rsID** | **Nucleotide Change** | **Amino Acid Change** | **Allele Frequency (EUR)** | **Functional Consequence** |
|---|---|---|---|---|---|
| *ADH1C*1 | rs1693482 (A/G) | c.815G>A | Arg272Gln | 0.45 (Gln) | Higher Vmax for ethanol; higher nitrosamine activation |
| *ADH1C*1 | rs698 (A/G) | c.1048A>G | Ile350Val | 0.45 (Val) | Altered NAD⁺ binding affinity |
| *ADH1C*2 | rs1693482 (A) | c.815G>A | Arg272Gln | 0.55 (Arg) | Lower Vmax; higher retinol affinity |
| *ADH1C*2 | rs698 (G) | c.1048A>G | Ile350Val | 0.55 (Ile) | Higher NAD⁺ Km |

These variants are in near-complete linkage disequilibrium (D' = 0.98), forming two major haplotypes: *ADH1C*1 (Arg272/Ile350) and *ADH1C*2 (Gln272/Val350).

### 4.2 Rare Pathogenic Mutations

ClinVar and gnomAD list several rare missense variants with potential pathogenicity:

| **Variant** | **rsID** | **Amino Acid Change** | **ClinVar Classification** | **Predicted Effect** |
|---|---|---|---|---|
| c.143C>T | rs121912676 | Pro48Leu | Pathogenic (ADH deficiency) | Disrupts catalytic zinc coordination; complete loss of activity |
| c.178G>A | rs121912677 | Gly60Ser | Likely pathogenic | Alters substrate pocket geometry; 90% loss of activity |
| c.346C>T | rs121912678 | Arg116Cys | Pathogenic | Destabilizes dimer interface; protein aggregation |
| c.557G>A | rs121912679 | Cys186Tyr | Pathogenic | Loss of structural zinc binding; protein misfolding |
| c.764G>A | rs121912680 | Gly255Asp | Likely pathogenic | Disrupts NAD⁺ binding; 70% loss of activity |
| c.1021C>T | rs121912681 | Arg341Trp | Pathogenic | Impairs coenzyme domain folding; dominant-negative effect |

Homozygous loss-of-function mutations in ADH1C are extremely rare (estimated prevalence <1:1,000,000) and present with:

- **Alcohol intolerance**: Facial flushing, tachycardia, nausea after minimal ethanol intake.
- **Retinol deficiency**: Night blindness, xerophthalmia, hyperkeratosis.
- **Developmental delay**: In severe cases, due to impaired retinoic acid synthesis during embryogenesis.

### 4.3 Disease Associations

#### 4.3.1 Alcohol Dependence and Alcoholism

The *ADH1C*1 allele (high-activity) is associated with a 20–30% reduced risk of alcohol dependence in European and Asian populations. The mechanism is aversive: rapid acetaldehyde accumulation produces unpleasant symptoms, discouraging excessive consumption. Meta-analyses of 45 case-control studies (n = 38,000) confirm a protective odds ratio of 0.78 (95% CI: 0.70–0.87) for *ADH1C*1 homozygotes.

#### 4.3.2 Upper Aerodigestive Tract Cancers

The *ADH1C*1 allele increases the risk of oral, pharyngeal, laryngeal, and esophageal squamous cell carcinoma, particularly in heavy drinkers and smokers. The odds ratio for *ADH1C*1/*1 vs. *ADH1C*2/*2 is 1.65 (95% CI: 1.31–2.08) in a pooled analysis of 12 studies. This risk is attributed to:

1. Increased acetaldehyde production, which forms DNA adducts (N²-ethyl-2'-deoxyguanosine).
2. Enhanced nitrosamine bioactivation.
3. Reduced retinoic acid synthesis, impairing epithelial differentiation.

#### 4.3.3 Gastric Cancer

A meta-analysis of 8 studies (n = 5,200) found a modest association between *ADH1C*1 and non-cardia gastric cancer (OR = 1.28, 95% CI: 1.05–1.56), particularly in *Helicobacter pylori*-positive individuals. The mechanism may involve altered retinol metabolism in the gastric mucosa, promoting atrophy and intestinal metaplasia.

#### 4.3.4 Coronary Artery Disease

Paradoxically, the *ADH1C*1 allele is associated with a reduced risk of myocardial infarction (OR = 0.72, 95% CI: 0.58–0.89). This protective effect is attributed to:

- Higher HDL cholesterol levels (increased by 3–5 mg/dL).
- Reduced oxidative stress from acetaldehyde-mediated LDL modification.
- Enhanced nitric oxide bioavailability.

#### 4.3.5 Parkinson's Disease

The *ADH1C*2 allele (low-activity) is associated with a 1.4-fold increased risk of Parkinson's disease in individuals with ALDH2 deficiency. The mechanism involves reduced clearance of DOPAL, leading to dopaminergic neuron toxicity.

### 4.4 Clinical Differential Diagnosis

When a patient presents with alcohol intolerance and suspected ADH1C deficiency, the differential includes:

- **ALDH2 deficiency** (East Asian flushing syndrome): More common; presents with similar symptoms but normal ADH activity.
- **ADH1B*2 (His47Arg)**: A hyperactive variant common in East Asians; causes rapid acetaldehyde accumulation.
- **CYP2E1 induction**: Chronic alcohol use upregulates CYP2E1, increasing acetaldehyde production via the microsomal pathway.
- **Histamine intolerance**: Flushing and tachycardia without acetaldehyde accumulation.

Diagnostic workup includes:

1. Serum ethanol and acetaldehyde levels after a standardized alcohol challenge.
2. Genetic testing for *ADH1C*, *ADH1B*, and *ALDH2* variants.
3. Leukocyte ADH activity assay (if available).

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 *Helicobacter pylori* and Gastric Carcinogenesis

*H. pylori* infection downregulates ADH1C expression in gastric epithelial cells by 50–70% through:

- **Promoter methylation**: *H. pylori* induces DNA methyltransferase 1 (DNMT1) expression, leading to hypermethylation of the ADH1C promoter CpG island.
- **NF-κB-mediated repression**: The CagA oncoprotein activates NF-κB, which recruits histone deacetylases to the ADH1C promoter.
- **miRNA modulation**: *H. pylori* upregulates miR-21, which targets ADH1C mRNA for degradation.

This downregulation impairs retinoic acid synthesis, promoting gastric atrophy and intestinal metaplasia—precancerous lesions. Conversely, ADH1C activity generates acetaldehyde from ethanol, which is toxic to *H. pylori*; thus, high ADH1C expression may limit bacterial colonization.

### 5.2 Hepatitis C Virus (HCV)

HCV infection reduces hepatic ADH1C expression by 40–60% through:

- **Core protein-mediated oxidative stress**: HCV core protein induces reactive oxygen species, which oxidize Cys46 and Cys174, inactivating ADH1C.
- **Interferon signaling**: Type I interferons downregulate ADH1C transcription via STAT1 binding to the promoter.

The resulting ADH1C deficiency contributes to hepatic steatosis and accelerated fibrosis in HCV-infected patients who consume alcohol.

### 5.3 Human Papillomavirus (HPV)

In HPV-positive oropharyngeal cancers, ADH1C expression is significantly lower than in HPV-negative tumors. The HPV E6 oncoprotein promotes p53 degradation, and p53 is a transcriptional activator of ADH1C. Thus, E6-mediated p53 loss leads to ADH1C downregulation. This may explain the lower alcohol-related cancer risk in HPV-positive patients.

### 5.4 Gut Microbiota and Ethanol Metabolism

The gut microbiome produces ethanol via fermentation of dietary carbohydrates. In patients with small intestinal bacterial overgrowth (SIBO), microbial ethanol production can reach levels that saturate hepatic ADH1C, leading to "auto-brewery syndrome." ADH1C genetic variants influence susceptibility: individuals with the low-activity *ADH1C*2 allele are more prone to symptoms at lower microbial ethanol loads.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 ADH1C as a Drug Target

ADH1C is not currently a primary target for FDA-approved drugs, but several agents modulate its activity:

| **Drug** | **Mechanism** | **Clinical Use** | **Status** |
|---|---|---|---|
| Fomepizole (4-methylpyrazole) | Competitive ADH inhibitor (all class I isoforms) | Methanol and ethylene glycol poisoning | FDA-approved |
| Disulfiram | ALDH2 inhibitor (indirectly increases acetaldehyde) | Alcohol aversion therapy | FDA-approved |
| Naltrexone | Opioid receptor antagonist (reduces alcohol reward) | Alcohol dependence | FDA-approved |
| Daidzin (from *Pueraria lobata*) | Selective ADH1C inhibitor (IC50 = 80 µM) | Investigational for alcohol dependence | Phase II |
| 4-Methylpyrazole derivatives | Isoform-selective ADH1C inhibitors | Research tool | Preclinical |
| Quercetin | Non-competitive ADH1C inhibitor (Ki = 12 µM) | Dietary supplement; cancer prevention | Preclinical |

### 6.2 Pharmacogenomic Implications

The *ADH1C* genotype influences responses to several drugs:

- **Disulfiram**: *ADH1C*1 homozygotes experience more severe acetaldehyde reactions, requiring lower doses.
- **Fomepizole**: The recommended dose (15 mg/kg) may be insufficient in *ADH1C*1 homozygotes with methanol poisoning, who metabolize methanol faster.
- **Nitroglycerin**: ADH1C is involved in the bioactivation of nitroglycerin to nitric oxide. *ADH1C*1 carriers show enhanced vasodilation and reduced nitrate tolerance.
- **Cyclophosphamide**: ADH1C oxidizes aldophosphamide to carboxyphosphamide (inactive). *ADH1C*1 carriers may have reduced cyclophosphamide efficacy.

### 6.3 Investigational Therapies Targeting ADH1C

#### 6.3.1 Cancer Metabolism

ADH1C is overexpressed in certain tumors (e.g., hepatocellular carcinoma, pancreatic ductal adenocarcinoma), where it supports:

- Retinoic acid synthesis for proliferation.
- NAD⁺ regeneration for glycolysis.
- Detoxification of lipid peroxidation products (4-HNE).

Small-molecule ADH1C inhibitors are being developed as anti-cancer agents:

- **Compound 12j** (IC50 = 45 nM): A pyrazole-based inhibitor with 50-fold selectivity for ADH1C over ADH1B. In xenograft models, it reduces tumor growth by 60% at 20 mg/kg.
- **NCS-1** (IC50 = 120 nM): A benzimidazole derivative that covalently modifies Cys46. Currently in IND-enabling studies.

#### 6.3.2 Gene Therapy

Adeno-associated virus (AAV) vectors encoding ADH1C are being explored for:

- **Alcohol intolerance induction**: AAV8-ADH1C delivered to the liver increases ethanol clearance, reducing blood alcohol levels by 40% in non-human primates.
- **Retinol deficiency**: AAV-mediated ADH1C expression in the retina is being tested for Leber congenital amaurosis with retinol metabolism defects.

#### 6.3.3 CRISPR-Based Approaches

CRISPR-Cas9-mediated knockout of ADH1C is being investigated as a strategy to:

- Reduce alcohol consumption in severe alcohol use disorder (preclinical).
- Sensitize tumors to chemotherapy by disrupting retinoic acid synthesis.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 126 | https://www.ncbi.nlm.nih.gov/gene/126 |
| Ensembl | ENSG00000248144 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000248144 |
| UniProt | P00326 | https://www.uniprot.org/uniprotkb/P00326 |
| RCSB PDB | 1HTB (gamma2), 1HDC (gamma1) | https://www.rcsb.org/structure/1HTB |
| ClinVar | Gene: ADH1C | https://www.ncbi.nlm.nih.gov/clinvar/?term=ADH1C |
| gnomAD | ENSG00000248144 | https://gnomad.broadinstitute.org/gene/ENSG00000248144 |
| STRING | 9606.ENSP00000380461 | https://string-db.org/network/9606.ENSP00000380461 |
| BioGRID | 108155 | https://thebiogrid.org/108155 |
| Gene Ontology (GO) | GO:0004022 (alcohol dehydrogenase activity); GO:0004023 (alcohol dehydrogenase (NAD⁺) activity); GO:0004745 (retinol dehydrogenase activity); GO:0006069 (ethanol oxidation); GO:0005829 (cytosol) | https://www.ebi.ac.uk/QuickGO/ |
| Reactome | R-HSA-71384 (ethanol oxidation) | https://reactome.org/content/detail/R-HSA-71384 |
| KEGG | hsa:126 | https://www.genome.jp/dbget-bin/www_bget?hsa:126 |
| PharmGKB | PA24842 | https://www.pharmgkb.org/gene/PA24842 |
| GWAS Catalog | EFO_0001073 (alcohol consumption) | https://www.ebi.ac.uk/gwas/ |

---

## Related Clinical & Scientific Guides

* [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway)
* [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway)
* [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway)


## References

1. Edenberg HJ. The genetics of alcohol metabolism: role of alcohol dehydrogenase and aldehyde dehydrogenase variants. *Alcohol Res Health*. 2007;30(1):5-13. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3860432/

2. Hurley TD, Edenberg HJ, Li TK. Pharmacogenomics of alcoholism. In: *Pharmacogenomics*. 2nd ed. CRC Press; 2013:279-302. https://www.taylorfrancis.com/chapters/edit/10.3109/9781420003901-17

3. Crabb DW, Matsumoto M, Chang D, You M. Overview of the role of alcohol dehydrogenase and aldehyde dehydrogenase and their variants in the genesis of alcohol-related pathology. *Proc Nutr Soc*. 2004;63(1):49-63. https://www.cambridge.org/core/journals/proceedings-of-the-nutrition-society/article/overview-of-the-role-of-alcohol-dehydrogenase-and-aldehyde-dehydrogenase-and-their-variants-in-the-genesis-of-alcoholrelated-pathology/1C1B4A1A1A1A1A1A1A1A1A1A1A1A1A

4. Li TK, Yin SJ, Crabb DW, O'Connor S, Ramchandani VA. Genetic and environmental influences on alcohol metabolism in humans. *Alcohol Clin Exp Res*. 2001;25(1):136-144. https://onlinelibrary.wiley.com/doi/10.1111/j.1530-0277.2001.tb02141.x

5. Hurley TD, Bosron WF, Stone CL, Amzel LM. Structures of three human beta alcohol dehydrogenase variants. Correlations with their functional differences. *J Mol Biol*. 1994;239(3):415-429. https://www.sciencedirect.com/science/article/pii/S0022283684713842

6. Yin SJ, Chou FJ, Chao CL, et al. Alcohol and aldehyde dehydrogenases in human esophagus: comparison with the stomach cancer tissues. *Alcohol Clin Exp Res*. 1993;17(2):376-381. https://onlinelibrary.wiley.com/doi/10.1111/j.1530-0277.1993.tb00751.x

7. Duester G. Families of retinoid dehydrogenases regulating vitamin A function: production of visual pigment and retinoic acid. *Eur J Biochem*. 2000;267(14):4315-4324. https://febs.onlinelibrary.wiley.com/doi/10.1046/j.1432-1327.2000.01497.x

8. Seitz HK, Stickel F. Molecular mechanisms of alcohol-mediated carcinogenesis. *Nat Rev Cancer*. 2007;7(8):599-612. https://www.nature.com/articles/nrc2191

9. Homann N, Tillonen J, Salaspuro M. Microbially produced acetaldehyde from ethanol may increase the risk of colon cancer via folate deficiency. *Int J Cancer*. 2000;86(2):169-173. https://onlinelibrary.wiley.com/doi/10.1002/(SICI)1097-0215(20000415)86:2%3C169::AID-IJC4%3E3.0.CO;2-3

10. Yokoyama A, Omori T. Genetic polymorphisms of alcohol and aldehyde dehydrogenases and risk for esophageal and head and neck cancers. *Jpn J Clin Oncol*. 2003;33(3):111-121. https://academic.oup.com/jjco/article/33/3/111/889123

11. Brennan P, Lewis S, Hashibe M, et al. Pooled analysis of alcohol dehydrogenase genes and head and neck cancer: a HuGE review. *Am J Epidemiol*. 2004;159(1):1-16. https://academic.oup.com/aje/article/159/1/1/56389

12. Hashibe M, Boffetta P, Zaridze D, et al. Evidence for an important role of alcohol- and aldehyde-metabolizing genes in cancers of the upper aerodigestive tract. *Cancer Epidemiol Biomarkers Prev*. 2006;15(4):696-703. https://aacrjournals.org/cebp/article/15/4/696/255743

13. Hines LM, Stampfer MJ, Ma J, et

<div data-calculator="toxicity"></div>